[1] 张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识[J].中国骨质疏松杂志,2014, 20(9):1007-1010.
[2] 胡军,张华,牟青.骨质疏松症的流行病学趋势与防治进展[J].临床荟萃,2011,26(8):729-731.
[3] 单祎娜,王莉.骨质疏松症诊断和治疗进展[J].医学综述,2019,25(18):3652-3661.
[4] 仇宋明,尹恒,王建伟.基于“脾肾相关”论治疗骨质疏松症的研究进展[J].中国骨质疏松杂志,2019,25(12):1809-1816.
[5] 高子任,李跃华.中医血瘀证与骨质疏松症关系的研究[J].中华中医药杂志,2017,32(11): 5154-5157.
[6] 郭鱼波,王丽丽, 马如风, 等.骨质疏松的中医病因病机分析及其中医药治疗的前景探讨[J].世界科学技术—中医药现代化,2015,17(4):768-772.
[7] 阎博昭,李刚,许波,等.丹参治疗股骨头坏死的分子机制研究[J].安徽中医药大学学报,2018, 37(5):62-68.
[8] 白璧辉,谢兴文,黄晋,等.丹参及其有效成分防治骨质疏松症研究概况[J]. 中医药临床杂志, 2018,30(5):813-816.
[9] 莫朝伦,张军梅,贾莹, 等.丹参酮Ⅱ-A 对大鼠成骨细胞体外增殖分化的影响[J].贵阳医学院学报,2016,41(4):391-394.
[10] 桑龙,韩红德,吴克第, 等.丹参素通过核因子κB受体活化因子配体通路 抑制破骨细胞分化治疗大鼠骨质疏松症的研究[J].中国临床药理学杂志,2019,35(23):3072-3076.
[11] 陈海彬,周红光,李文婷,等. 网络药理学——中药复方作用机制研究新视角[J].中华中医药杂志,2019,34(7):2873-2876.
[12] PEI T, ZHENG C, HUANG C, et al. Systematic understanding the mechanisms of vitiligo pathogenesis and its treatment by Qubaibabuqi formula.J Ethnopharmacol. 2016;190:272-287.
[13] 甘东浩,薛海鹏,陈德强,等.基于网络药理学探讨骨碎补抗骨质疏松的物质基础及作用机制[J].中国实验方剂学杂志,2019,25(13):186-191.
[14] MOMOTA R, OHTSUKAA. Network of anatomical texts(NAnaTex),an open-source project for visualizing the interaction between anatomical terms.Anat Science Int.2018;93(1):149-153.
[15] FRANCESCHINI A, SZKLARCZYK D, FRANKILD S, et al.STRING V9.1: Protein-Protein Interaction Networks, with Increased Coverage and Integration.Nucleic Acids Res. 2013;41(Database issue):D808-815.
[16] 徐森楠,庄莉,翟园园,等,基于网络药理学研究二至丸防治骨质疏松症的物质基础与作用机制[J].中国药学杂志,2018.53(22): 1913-1920.
[17] JING Z, WANG C, YANG Q, et al. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro.J Cell Physiol. 2019;234(4):4472-4490.
[18] 郭威,李谌,李全营,等.丹参酮ⅡA对大鼠骨髓间充质干细胞成骨分化的影响[J].山东医药,2011,51(44):38-40.
[19] 曾克勤,武剑,强红伟,等.从瘀论治系统性红斑狼疮继发性骨质疏松症[J]. 中医学报, 2019, 34(248):199-203.
[20] 王雪鹏,李茂强,边振宇,等.PI3K/Akt信号通路在骨髓间充质干细胞增殖及成骨分化调控中的作用[J].中华骨质疏松和骨矿盐疾病杂志, 2014,7(3):250-257.
[21] CHEN LL, HUANG M, TAN JY, et al. PI3K/AKT pathway involvement in the osteogenic effects of osteoclast culture supernatants on preosteoblast cells.Tissue Eng Part A.2013;19:2226-2232.
[22] CZERNY B, KAMINSKI A, KURZAWSKI M, et al. The association of IL-1β, IL-2, and IL-6 gene polymorphisms with bone mineral density and osteoporosis in postmenopausal women.Eur J Obstet Gynecol Reprod Biol.2010;149(1):82-85.
[23] 尚国伟.小鼠骨髓间质干细胞成骨分化及促肾上腺皮质激素的影响[D].郑州:郑州大学,2014: 1-52.
[24] 张波,耿彬,谭小义,等.MAPK信号通路与骨质疏松关系的研究进展[J].中国矫形外科杂志, 2014, 22(23):2161-2164.
[25] 徐会金.运动通过p38MAPK信号通路对2型糖尿病小鼠骨代谢的影响[D].上海:华东师范大学, 2016.
[26] 陈亚辉,龚忠勤,崔燎.PI3K/Akt信号通路在骨质疏松病理过程中的作用[J].中国骨质疏松杂志, 2015,21(3):356-360.
[27] 高润涛,范志朋.丹参注射液促进人脱落乳牙牙髓干细胞成骨/成牙分化的实验研究[J].北京口腔医学,2018,26(2):65-68.
[28] ADAPALA NS,BARBE MF,TSYGANKOV AY,et al.Loss of Cbl-PI3K interaction enhances osteoclast survival due to p21-R as mediated PI3K activation independent of Cbl-b.J Cell Biochem.2014;115(7): 1277-1289.
[29] NAKCHBANDI IA.Osteoporosis and fractures in liver disease: Relevance, pathogenesis and therapeutic implications.World J Gastroenterol. 2014; 20(28): 9427- 9438.
[30] WIJARNPREECHA K, THONGPRAYOON C, PANJAWATANAN P, et al. Hepatitis C Virus Infection and Risk of Osteoporosis: A Meta-analysis. Gastroenterology. 2017;23:216-221.
[31] 黄陈恕,汤荣睿,易小翠.慢性乙型肝炎与骨质疏松相关性初步探讨[J].中国骨质疏松杂志. 2016.22(9):1136-1139.
[32] 黄英,杨颜茹.丙型肝炎后肝硬化与骨质疏松的临床研究[J].吉林医学,2012,33(23):4938-4939.
[33] 刘攀,姜睿.前列腺癌骨病诊断和治疗的进展[J].临床泌尿外科杂志,2016,31(8):762-766.
[34] HOFBAUER LC,RACHNER TD,COLEMAN RE,et al.endocrine asoects of bone metastases.Lancet Diabetes Endocrinol. 2014;2(6):500-502.
[35] YUAN FL,LI X,LU WG,et al.Type 17 T-helper cells might be a promising therapeutic target for osteoporosis.Mol Biol Rep. 2012;39(1):771-774.
[36] TYAGI AM, SRIVASTAVA K, MANSOORI MN, et al. Estrogen Deficiency Induces the Differentiation of IL-17 Secreting Th17 Cells: A New Candidate in the Pathogenesis of Osteoporosis.PLoS One. 2012; 7(9):e44552.
[37] 刘海.类风湿性关节炎并发骨质疏松患者骨密度、骨代谢指标与血清 IL-17、MMP-9水平的关系[J].河北医药,2015,37(17):2576-2579.
[38] 钟航,曹参,杨静,黄强.HIF-1信号通路与绝经后骨质疏松的关系研究[J].四川大学学报(医学版),2017,48(6):862-868.
[39] 黄文舟,殷嫦嫦,敖鹏, 等,晚期糖基化终末产物与骨性关节炎相关性的研究进展[J].中国矫形外科杂志,2017,25(9):820-823.
[40] REYNAERT NL, GOPAL P, RUTTEN EPA, et al. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to diseas.Int J Biochem Cell Biol.2016;81(Pt B): 403-418.
[41] Li G, Xu J, Li Z. Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling.Biochemical and biophysical research communications 2012;423(4):684-689. |